RBP, IGF2BP1 is overexpressed in non-small cell lung cancer (NSCLC) and linked with poor prognosis (in lung adenocarcinoma) at early onset: more than 3-fold elevated IGF2BP1 expression may be identified in 70% of NSCLCs, and it positively correlates with a 30% reduction in tumor-specific 5 years survival following surgery [111]. Here, IGF2BP1 is linked to non-small cell lung carcinoma.